BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 17574959)

  • 21. Several chromosomes involved in translocations with chromosome 5 shown with fluorescence in situ hybridization in patients with malignant myeloid disorders.
    Bram S; Rödjer S; Swolin B
    Cancer Genet Cytogenet; 2004 Nov; 155(1):74-8. PubMed ID: 15527906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescence in situ hybridization testing for -5/5q, -7/7q, +8, and del(20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study.
    Pitchford CW; Hettinga AC; Reichard KK
    Am J Clin Pathol; 2010 Feb; 133(2):260-4. PubMed ID: 20093235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
    Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
    Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isochromosome 5p and related anomalies: a novel recurrent chromosome abnormality in myeloid disorders.
    Herry A; Douet-Guilbert N; Morel F; Le Bris MJ; Guéganic N; Berthou C; De Braekeleer M
    Cancer Genet Cytogenet; 2010 Jul; 200(2):134-9. PubMed ID: 20620596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5q-: does longer survival of female patients explain the preponderance.
    Pedersen B
    Anticancer Res; 1997; 17(5A):3281-5. PubMed ID: 9413160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities.
    van der Straaten HM; van Biezen A; Brand R; Schattenberg AV; Egeler RM; Barge RM; Cornelissen JJ; Schouten HC; Ossenkoppele GJ; Verdonck LF;
    Haematologica; 2005 Oct; 90(10):1339-45. PubMed ID: 16219570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH.
    Shali W; Hélias C; Fohrer C; Struski S; Gervais C; Falkenrodt A; Leymarie V; Lioure B; Raby P; Herbrecht R; Lessard M
    Cancer Genet Cytogenet; 2006 Jul; 168(2):133-45. PubMed ID: 16843103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
    Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
    Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
    Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
    Larson RA; Le Beau MM
    Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
    Beyer V; Castagné C; Mühlematter D; Parlier V; Gmür J; Hess U; Kovacsovics T; Meyer-Monard S; Tichelli A; Tobler A; Jacky E; Schanz U; Bargetzi M; Hagemeijer A; de Witte T; van Melle G; Jotterand M
    Cancer Genet Cytogenet; 2004 Jul; 152(1):29-41. PubMed ID: 15193439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
    Cortes J; O'Brien S; Kantarjian H; Cork A; Stass S; Freireich EJ; Keating M; Pierce S; Estey E
    Leukemia; 1994 Dec; 8(12):2174-8. PubMed ID: 7808007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
    Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
    Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
    Larson RA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
    Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
    Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic analysis in patients with myelodysplastic syndrome.
    Hu N; Bian M
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(3):135-9. PubMed ID: 2098765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deletions of chromosome 5 in malignant myeloid disorders.
    Le Beau MM
    Cancer Surv; 1992; 15():143-59. PubMed ID: 1451109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.